Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder
- 8 October 2024
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 38 (12) , 985-1002
Abstract
Major depressive disorder (MDD) is a severe mental illness with a complex etiology. Currently, many medications employed in clinical treatment exhibit limitations such as delayed onset of action and a high incidence of adverse reactions. Therefore, there is a pressing need to develop antidepressants that exhibit enhanced efficacy and safety. The N-methyl-d-aspartate receptor (NMDAR), a distinctive glutamate-gated ion channel receptor, has been implicated in the onset and progression of depressive disorder, as evidenced by both preclinical and clinical research. The NMDAR antagonist, ketamine, exhibits rapid and sustained antidepressant effects, holding promise as a novel therapeutic approach for depressive disorder. However, its psychotomimetic impact and potential for addiction have restricted its widespread clinical application. Notably, over the past decade, studies have suggested that enhancing NMDAR functionality can produce antidepressant effects with improved safety, especially with the emergence of NMDAR-positive allosteric modulators (PAMs). We view this as a potential novel strategy for treating depression, forming the basis for the narrative review that follows.Keywords
Funding Information
- Major Research Development Program of Ningxia Hui Autonomous Region (2022BEG02043, 2022BEG02042)
- Natural Science Foundation of Ningxia Province (2022AAC03139)
This publication has 139 references indexed in Scilit:
- Changes in concentrations of NMDA receptor subunit GluN2B, Arc and syntaxin‐1 in dorsal hippocampus Schaffer collateral synapses in a rat learned helplessness model of depressionJournal of Comparative Neurology, 2021
- Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant DepressionJAMA Psychiatry, 2018
- Neuronal calcium signaling: function and dysfunctionCellular and Molecular Life Sciences, 2014
- A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depressionPsychopharmacology, 2013
- Molecular and Cellular Mechanisms of Antidepressant Action2012
- Immunolocalization of NMDA receptor subunit NR3B in selected structures in the rat forebrain, cerebellum, and lumbar spinal cordJournal of Comparative Neurology, 2008
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Ionotropic and metabotropic glutamate receptor structure and pharmacologyPsychopharmacology, 2005
- Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of SchizophreniaArchives of General Psychiatry, 1999
- Differential expression of five N‐methyl‐D‐aspartate receptor subunit mRNAs in the cerebellum of developing and adult ratsJournal of Comparative Neurology, 1994